Europe Blood Glucose Monitoring Devices Market Outlook, 2028

Europe Blood Glucose Monitoring Devices Market Outlook, 2028

The European blood glucose monitor market is a dynamic and sophisticated terrain within the field of medical equipment. Europe is at the forefront of diabetes management innovation, thanks to a population that welcomes new healthcare solutions. This market offers a mix of classic and cutting-edge monitoring technologies, catering to a wide range of healthcare needs throughout its various regions. The region's healthcare infrastructure, characterised by tight regulatory frameworks and an emphasis on patient-centric treatment, creates a competitive market driven by quality, accuracy, and technology improvements. As Europe deals with an increasing prevalence of diabetes and an ageing population, the blood glucose monitoring industry continues to expand, promising breakthroughs that will alter diabetes treatment standards across the continent. The burden of high diabetes costs is weighing heavily on European governments. According to the IDF, the total diabetes expenditure in Europe for those aged 20 to 79 years is USD 150 billion. Other IDF figures show that 21,600 children are added to the type 1 diabetes population pool each year. According to these estimates, diabetes accounts for around 9% of overall healthcare expenditure in Europe. CGMs are an excellent tool for patients who rely on insulin pumps or multiple daily injections (MDI) therapy to help improve glycemic balance without increasing the risk of severe hypoglycemia. As a result of the aforementioned reasons, the studied market is expected to increase throughout the anticipated period. Diabetes is becoming more common in Europe, increasing the requirement for effective monitoring methods. This predominance fuels the industry, emphasising the importance of accurate and easily available blood glucose monitors. The diabetes demography is influenced by Europe's ageing population. Blood glucose monitors serve the elderly population by providing user-friendly and innovative monitoring solutions that are in line with their healthcare requirements. Remote monitoring is made easier with the integration of blood glucose monitors with telemedicine. This breakthrough is especially useful for healthcare providers to remotely monitor patients' glucose levels, improving patient care and accessibility.

According to the research report ""Europe America Blood Glucose Monitoring Devices Market Outlook, 2028,"" published by Bonafide Research, the Europe Blood Glucose Monitoring Devices market was valued at USD 4 Billion in 2022. The region exemplifies an atmosphere that embraces and drives technical progress. This ethos is reflected in Europe's blood glucose monitor market, which continuously introduces cutting-edge improvements in sensor technology, networking features, and data management systems. The quick acceptance of these modern devices demonstrates Europe's readiness to incorporate technological progress into healthcare solutions, thereby setting a global standard for diabetes treatment innovation. Europe has a strong healthcare infrastructure, which is characterised by tight regulatory regimes that ensure the safety, quality, and efficacy of medical equipment. Compliance with high criteria, such as CE certification, demonstrates the market's commitment to providing trustworthy and clinically validated blood glucose monitors, building consumer trust and confidence in these products. Europe is a centre for healthcare research and development. Collaborations between academia, research institutes, and industry companies propel the advancement of blood glucose monitoring technology. This collaborative ecosystem drives innovation, influencing the market with technologies that prioritise accuracy, usability, and patient-centred design. Diabetes is a serious public health concern in Europe, affecting an estimated 50 million adults. Europe exemplifies a linked healthcare ecosystem in which blood glucose monitors interface smoothly with digital health platforms and electronic health data. This integration enables comprehensive patient data management, allowing healthcare providers to make educated decisions while also supporting the continuity of treatment.

Based on report market is divided into six major countries Germany, United Kingdom, France, Italy, Spain and Russia. Among them Germany is projected to lead the Europe blood glucose monitor market during the forecast period.

The German healthcare system is known for its efficiency and excellence. The country's well-developed healthcare infrastructure, which includes cutting-edge hospitals and healthcare facilities, makes widespread adoption of new medical technologies, like blood glucose monitors, possible. Germany has strong medical device regulation norms. Compliance with stringent quality and safety standards, such as CE marking, ensures the dependability and efficacy of blood glucose monitors, improving consumer trust and market supremacy. According to the German Diabetes Centre (DDZ) 2022, diabetes affects about 8.5 million people in Germany. The number of people with type 2 diabetes in Germany will climb during the next two decades. According to DDZ experts, up to twelve million people could be affected by metabolic issues by 2040. Germany has stringent data privacy regulations, such as the General Data Protection Regulation (GDPR), which protects diabetics' personal health information. This ensures that their information is gathered and managed ethically and responsibly. Germany is a major centre for diabetes research and development, with numerous universities and research facilities committed to the development of innovative diabetic medicines and technologies. Germany is known for being among the first to implement contemporary healthcare technologies. Its healthcare system prioritises technological innovations and is frequently an early adopter, creating an environment conducive to the development and uptake of novel blood glucose monitoring equipment. Germany has an advanced healthcare infrastructure, which includes a network of hospitals, clinics, and healthcare providers. This infrastructure enables the widespread distribution of blood glucose monitoring devices, ensuring accessibility in a variety of locations.

Based on product market is segmented into self-monitoring devices and continuous blood glucose monitoring devices. Self-monitoring devices dominates the Europe blood glucose monitor market.

The convenience they provide is critical. Individuals can track their blood glucose levels at home using self-monitoring equipment, eliminating the need for frequent visits to healthcare institutions. This convenience is especially important for diabetic people who require regular monitoring because it allows them to manage their health more successfully on a daily basis. Furthermore, technological developments in these devices have contributed greatly to their dominance. Bluetooth connectivity, smartphone integration, and user-friendly interfaces are common aspects of modern self-monitoring systems. These features not only make monitoring easier, but they also enable seamless data sharing with healthcare providers, allowing for improved management and prompt treatments. Another important reason is the growing prevalence of diabetes in Europe. As the number of people diagnosed with diabetes continues to climb, so does the demand for effective and accessible monitoring systems. Self-monitoring devices meet this desire by providing a practical and dependable way for patients to frequently test their glucose levels, empowering them to take control of their health. Furthermore, developments in healthcare reimbursement regulations, as well as the availability of these devices via multiple distribution channels, have contributed to their supremacy. Better reimbursement alternatives make these devices more accessible and inexpensive for patients, enabling increased regional adoption.

Based on end user segment market includes, hospitals, home care, and diagnostic centers. Hospitals are major end user blood glucose monitor in Europe.

Inpatients and outpatients in hospitals require precise and reliable blood glucose monitoring, especially those with serious illnesses such as diabetes, gestational diabetes, or those having surgery. They rely on modern blood glucose monitoring systems to closely monitor patients' levels, ensuring timely treatments and proper blood sugar management. Hospitals see a diverse range of patients with various medical needs. They frequently have specialised equipment and a qualified healthcare team that can handle a wide range of conditions, including crucial diabetes management. As a result, hospitals serve as a key centre for the use of modern blood glucose monitoring devices that cater to a variety of patient needs. Hospitals handle extensive patient information, making it critical to include blood glucose monitoring data into electronic health records (EHRs). Hospitals frequently use systems that allow for the seamless integration of blood glucose measurements into these records, ensuring continuity of care and thorough patient histories. In the case of medical equipment and gadgets, hospitals must conform to severe regulatory norms. They typically invest in dependable, licenced blood glucose monitors that satisfy regulatory requirements, ensuring patient safety and compliance with healthcare standards.

Companies Covered in this report:

F. Hoffmann-La Roche AG, Abbott Laboratories, Nipro Corporation, B. Braun Melsungen AG, Medtronic plc, DexCom, Inc, Ypsomed AG, Bionime Corporation.

Considered in this report:

• Geography: Europe
• Historic year: 2017
• Base year: 2022
• Estimated year: 2023
• Forecast year: 2028

Aspects covered in this report:

• Europe Blood Glucose Monitor market Outlook with its value and forecast along with its segments
• Country-wise Blood Glucose Monitor market analysis
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

Country covered in the report:

• Germany
• United Kingdom
• France
• Italy
• Spain
• Russia

By Product

• Self-monitoring Devices
• Continuous Blood Glucose Monitoring Devices

By End User

• Hospitals
• Home Care
• Diagnostic Centers

By Indication

• Diabetes
• Pregnancy
• Cardiovascular Disorders & Hypertension
• Cancer
• Respiratory Diseases
• Movement Disorders
• Hearing Disorders
• Wound Care
• Other Indications (sleep disorders, kidney disorders, neurovascular diseases, and HIV)

The approach of the report:

This report consists of a combined approach of primary and secondary research. Initially, secondary research was used to get an understanding of the market and list the companies that are present in it. The secondary research consists of third-party sources such as press releases, annual reports of companies, and government-generated reports and databases. After gathering the data from secondary sources, primary research was conducted by conducting telephone interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this; we have started making primary calls to consumers by equally segmenting them in regional aspects, tier aspects, age group, and gender. Once we have primary data with us, we can start verifying the details obtained from secondary sources.

Intended audience:

This report can be useful to industry consultants, manufacturers, suppliers, associations, and organisations related to the Blood Glucose Monitor industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing and presentations, it will also increase competitive knowledge about the industry.

***Please Note: It will take 48 hours (2 Business days) for delivery of the report upon order confirmation.